No Data
Genscript Bio (01548.HK): Legend Biotech announces the release of a report at the 2024 ASH annual meeting.
On December 10, Guolonghui reported that GENSCRIPT BIO (01548.HK) announced that on December 10, 2024 (before the Hong Kong trading session on December 10), Legend Biotech released a press release, announcing the latest data from the Phase 3 study CARTITUDE-4. The study results indicate that in patients with relapsed or lenalidomide-refractory multiple myeloma who have previously received at least first-line treatment (including a proteasome inhibitor (PI) and an immunomodulatory drug (IMiD)), compared to standard therapy (pomalidomide, bortezomib, and dexamethasone (PVd) or daratumumab, pomalidomide...
FDA Grants IND Approval to Base Therapeutics' Base-Edited NK Cell Therapy, Powered by GenScript's CGMP SgRNA and CytoSelect Platform
The U.S. bioterrorism law has undergone significant changes, the CRO concept has launched a major counterattack, and WuXi AppTec is excited!
Industry pessimistic expectations may improve.
Honkong stock market movement | CRO concept stocks collectively opened higher as the bioprotective legislation was not included in the final version of the NDAA by the U.S. Senate and House of Representatives.
CRO concept stocks opened higher collectively. As of the time of writing, wuxi bio (02269) increased by 13.03%, trading at 19.6 Hong Kong dollars; wuxi apptec (02359) rose by 11.72%, trading at 61 Hong Kong dollars; pharmaron (03759) climbed by 9.14%, trading at 16 Hong Kong dollars.
How to break through the challenges in the development of innovative drugs? The industry suggests focusing on internationalization.
① The year 2024 will be the inaugural year of large-scale authorized trade, and going abroad has become an important direction for the development of local pharmaceutical companies; ② Chinese企业品牌, clinical trial capabilities, data presentation formats, and levels of international operation still need time and practical verification.
Trending Industry Today: WUXI APPTEC Leads Gains In CRO Stocks
Genscript Biotech Corporation's (HKG:1548) P/S Is Still On The Mark Following 29% Share Price Bounce
No Data
